The OVIVA trial asked whether oral antibiotics could replace IV antibiotics for the first 6 weeks of treatment in complex bone and joint infections. It enrolled 1054 adults across 26 UK centers with osteomyelitis, prosthetic joint infection, or hardware infection. The primary endpoint was definitive treatment failure at 1 year.
For decades, the standard of care for osteomyelitis and prosthetic joint infection was 6 weeks of IV antibiotics, a practice rooted in a 1970 expert-opinion paper rather than trial evidence. OVIVA changed that — it is now the foundational RCT justifying oral step-down therapy for most bone and joint infections.
When your ID consultant recommends switching a post-debridement osteomyelitis patient to oral antibiotics at week 1 or 2, this is the paper behind that decision. The key caveat: oral therapy requires a pathogen with a susceptible oral agent and a patient with intact enteral absorption — if either is missing, IV therapy remains necessary.
The 9.4% catheter complication rate in the IV group is worth internalizing: prolonged PICC lines are not benign, and avoiding them is itself a meaningful clinical benefit.
The OVIVA trial asked whether oral antibiotics could replace IV antibiotics for the first 6 weeks of treatment in complex bone and joint infections. It enrolled 1054 adults across 26 UK centers with osteomyelitis, prosthetic joint infection, or hardware infection. The primary endpoint was definitive treatment failure at 1 year.
For decades, the standard of care for osteomyelitis and prosthetic joint infection was 6 weeks of IV antibiotics, a practice rooted in a 1970 expert-opinion paper rather than trial evidence. OVIVA changed that — it is now the foundational RCT justifying oral step-down therapy for most bone and joint infections.
When your ID consultant recommends switching a post-debridement osteomyelitis patient to oral antibiotics at week 1 or 2, this is the paper behind that decision. The key caveat: oral therapy requires a pathogen with a susceptible oral agent and a patient with intact enteral absorption — if either is missing, IV therapy remains necessary.
The 9.4% catheter complication rate in the IV group is worth internalizing: prolonged PICC lines are not benign, and avoiding them is itself a meaningful clinical benefit.